Adamis Pharmaceuticals Corporation [ADMP] took an upward turn with a change of 1.43%, trading at the price of $1.42 during the trading session on Thursday. The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 783861 shares changed hands being bought and sold, while Adamis Pharmaceuticals Corporation shares have an average trading volume of 350.70K shares for that time period. ADMP monthly volatility recorded N/A, in the meanwhile having share price volatility for the week set at N/A. PS value for ADMP stocks is 4.05 with PB recorded at 1.67.

Adamis Pharmaceuticals Corporation [NASDAQ:ADMP]: Analyst Rating and Earnings

Stock market traders frequently keep their eyes on what Wall Street experts as it relates to a potential investment. For Adamis Pharmaceuticals Corporation [ADMP], the most recent analyst consensus recommendation available since its latest financial results for the quarter ending in December. On average, stock market experts give ADMP an Outperform rating. Its stock price has been found in the range of 1.20 to 4.25. This is compared to its latest closing price of $1.40.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Adamis Pharmaceuticals Corporation [ADMP] is sitting at 2.33. This is compared to 1 month ago, when its average rating was 2.33.

Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Fri 9 Aug (In 25 Days).

Fundamental Analysis of Adamis Pharmaceuticals Corporation [ADMP]

Now let’s turn to look at profitability: with a current Operating Margin for Adamis Pharmaceuticals Corporation [ADMP] sitting at -267.47 and its Gross Margin at +14.51.

This company’s Return on Total Capital is -85.96, and its Return on Invested Capital has reached -79.30%. Its Return on Equity is -90.46, and its Return on Assets is -71.08. These metrics suggest that this Adamis Pharmaceuticals Corporation does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Adamis Pharmaceuticals Corporation [ADMP] has generated a Total Debt to Total Equity ratio of 5.53. Similarly, its Total Debt to Total Capital is 5.24, while its Total Debt to Total Assets stands at 4.43.

What about valuation? This company’s Enterprise Value to EBITDA is -1.19. The Enterprise Value to Sales for this firm is now 2.63, and its Total Debt to Enterprise Value stands at 0.04. Adamis Pharmaceuticals Corporation [ADMP] has a Price to Book Ratio of 2.28.

Shifting the focus to workforce efficiency, Adamis Pharmaceuticals Corporation [ADMP] earns $99,254 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 15.20 and its Total Asset Turnover is 0.27. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.93 and its Current Ratio is 2.21. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Adamis Pharmaceuticals Corporation [ADMP] has 48.65M shares outstanding, amounting to a total market cap of $68.11M. Its stock price has been found in the range of 1.20 to 4.25. At its current price, it has moved down by -66.59% from its 52-week high, and it has moved up 18.33% from its 52-week low.

This stock’s Relative Strength Index (RSI) is at 50.17. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Adamis Pharmaceuticals Corporation [ADMP] a Reliable Buy?

Adamis Pharmaceuticals Corporation [ADMP] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.